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ABSTRACT 
 
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia 
characterized by complement-mediated intravascular hemolysis that is effectively 
treated with eculizumab. However, treatment responses are reported heterogeneous 
with some patients presenting residual hemolysis and requiring RBC transfusions. 
Recent reports have shown that both extravascular hemolysis and incomplete C5 
blockade can explain these suboptimal hematological responses. Here we have tested 
our eculizumab-treated PNH patients (n=12) for signs of hemolysis and assessed 
complement biomarkers. Patients were also genotyped for complement receptor 1 
(CR1, CD35) and C5 polymorphisms and evaluated for free eculizumab in plasma. We 
report that 10 patients (83%) present parameters suggesting persistent hemolysis, 
although they did not require additional transfusions. Seven of them (58%) become 
direct Coombs-test positive as a consequence of treatment, including all patients 
carrying the low-expression CR1-L allele. CH50 and sC5b-9 assays demonstrate that 
the persistent low-level hemolysis identified in our treated patients is not a 
consequence of incomplete C5 blockade, supporting that this hemolysis, as has been 
suggested previously, results from the extravascular removal of C3 opsonized PNH 
erythrocytes. We also show that continuous alternative pathway activation in 
eculizumab-treated individuals carrying the CR1-L allele results in abnormally 
decreased levels of C3 in plasma that could, potentially, increase their susceptibility to 
bacterial infections. Finally, we encourage a routine evaluation of free eculizumab 
levels and terminal pathway activity to personalize eculizumab administration. 
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INTRODUCTION 
Paroxysmal Nocturnal Hemoglobinuria (PNH) is a disorder caused by the 
proliferation of hematopoietic stem cells carrying, in most of the cases, a somatic 
mutation in the gene PIG-A, which is necessary for the biosynthesis of the glycosil 
phosphatidyl-inositol (GPI) anchor.  As a consequence, PNH erythrocytes (PNH-E) 
lack, among other proteins, the complement regulators decay accelerating factor (DAF; 
CD55) and membrane inhibitor of reactive lysis (MIRL; CD59) and become susceptible 
to complement-mediated intravascular hemolysis.(Wilcox, et al., 1991, Takeda, et al., 
1993, Miyata, et al., 1993) PNH is effectively treated with eculizumab, a monoclonal 
antibody that blocks C5 cleavage, impeding activation of the lytic pathway and 
membrane attack complex (MAC) formation.(Thomas, et al., 1996, Rother, et al., 2007, 
Hillmen, et al., 2004) Eculizumab treatment prevents intravascular hemolysis, which 
abolishes thrombotic events, the main cause of death in PNH, and results in marked 
improvement of all clinical parameters and the quality of life of the patients.(Hillmen, et 
al., 2006, Brodsky, et al., 2008) Despite the unquestionable benefits of eculizumab, the 
responses to treatment are reported heterogeneous, with most treated patients 
presenting signs of continuous low-level hemolysis and 25-35% of them still requiring 
red blood cell (RBC) transfusions.(Brodsky, et al., 2008, Luzzatto, et al., 2011, Kelly, et 
al., 2011) In addition to lytic pathway dysregulation, absence of CD55 and CD59 in 
PNH-E also impairs regulation of the complement alternative pathway, a situation that 
persists under eculizumab treatment and that results in intense deposition of activated 
C3 fragments on the PNH-E surface.(Logue, et al., 1973) As a consequence of the 
accumulation of C3 opsonized PNH-E, several eculizumab-treated patients become 
direct Coombs-test positive.(Roth, et al., 2010, Hill, et al., 2010) C3 opsonized PNH-E 
are susceptible of extravascular clearance through the reticuloendothelial system in the 
liver and the spleen.(Jaffe, et al., 1976, Ross and Lambris, 1982, Lin, et al., 2015) This 
alternative removal mechanism of PNH-E, which is unmasked by the blockade of the 
lytic pathway-mediated intravascular hemolysis of the PHN-E by eculizumab, is thought 
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to be the cause of the on-going residual hemolysis that present many treated PNH 
patients.(Hill, et al., 2010, Risitano, et al., 2009) Critically, it has also been found that 
the intensity of complement deposition in PNH-E inversely correlates with the levels of 
the complement regulator CR1 (CD35) on erythrocytes, which are determined by 
genetic variants at the CR1 locus;(Rodriguez de Cordoba and Rubinstein, 1986, 
Wilson, et al., 1986) individuals carrying the low expression allele CR1-L being 
particularly susceptible to experience extravascular hemolysis under eculizumab 
treatment.(Rondelli, et al., 2014) In addition to this extravascular removal of heavily 
opsonized PNH-E, one study has recently indicated that the residual low-level 
hemolysis could, in some patients, be related to incomplete C5 blockade and 
recommended close supervision of free eculizumab levels and terminal pathway 
activity to prevent this possibility.(Peffault de Latour, et al., 2015)  
Here, we searched for correlations between hemolysis parameters, complement 
determinations (including CR1 H/L genotypes) and plasma levels of free eculizumab in 
our cohort of eculizumab-treated patients. We show that most eculizumab-treated 
patients presented signs of low-level hemolysis. Importantly, this residual hemolysis 
has no clinical manifestations in our patients. We also show that evaluation of the free 
eculizumab levels and terminal pathway activity may help to improve rationalization of 
the eculizumab administration and that eculizumab-treated individuals carrying the 
CR1-L allele may require special attention as they may be predisposed to present 
more severe disease presentations and susceptibility to infections. 
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PATIENTS, MATERIALS AND METHODS 
Subjects. 
The studies reported here have Institutional Review Board’s approval. Informed 
consent was provided to all individuals participating in the study, according to the 
Declaration of Helsinki. The study group included 12 patients who were diagnosed of 
having PNH using flow cytometry techniques, as reported previously.(Munoz-Linares, 
et al., 2014) The average age of the patients was 48 years. Eleven were classified as 
classic-PNH and one as aplasia anemia-PNH, according to the classification of 
Nakakuma as amended by Parker.(Nakakuma, et al., 1995, Parker, et al., 2005) All 
patients in our series have received eculizumab because of severe hemolysis, PNH 
clone granulocytes percentage >45% and severe symptoms attributable to the disease, 
causing serious impairments in their quality of life. All patients included in the study 
have been receiving eculizumab for more than one year (ranging between 1yr and 8yr; 
mean 4.3±2.1yr). Eculizumab was administrated intravenously following standard 
guidelines. In all cases, transfusion independence was achieved at the beginning of 
treatment with disappearance of the symptomatology attributable to the disease. Nine 
patients have always received 900mg of the drug every 14d and three patients, due to 
a breakthrough hemolysis, required a dosing increase that have been maintained since 
then at 1200mg every 2wk. All 12 patients have received prophylactic vaccination with 
meningococcal tetravalent vaccine and are revaccinated every 2yr. Since the 
beginning of 2013, all patients have received ciprofloxacin 500mg/d orally (or penicillin 
oral 400mg/12h). In the last months all the patients has been vaccinated with anti-
meningococcus B (Bexsero).  
We collected samples from all patients treated during 4 weeks (two eculizumab 
cycles), at three different points during treatment; before and after eculizumab 
administration and in the intermediate week between two eculizumab cycles.  
Parameters, such as levels of lactate dehydrogenase (LDH), bilirubin, % of 
reticulocytes, hemoglobin and Coombs-test data were determined only in the samples 
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collected before the eculizumab administration and in the intermediate week. None of 
the patients had clinical complications during the length of the study. 
 
Genotyping 
Genomic DNA was prepared from peripheral blood cells of all individuals included in 
these studies according to standard procedures.(Miller, et al., 1988) Patients were 
genotyped for the three polymorphisms in CR1 gene that allow discrimination of the 
CR1-H and CR1-L alleles by automatic DNA sequencing of PCR amplified fragments. 
To amplify a fragment that includes the HindIII RFLP (intron 27) we used the forward 
primer 5´-GGGTTCTTGCTCTTGACTTC-3´ and the reverse primer 5´- 
GAATGCTGGACTGTCTTGC-3´. To amplify the region that includes the H1208R 
(exon22) site we used the forward primer 5´-CCTTGTGCTAGGGAGAATTG-3´ and the 
reverse primer 5´-CCAGAGGTTAATCTCCCTG-3´ and for the P1827R (exon 33) we 
used the forward primer 5´-TCCAGGAACACTGTCTTTG-3´ and the reverse primer 5´-
TGACAGTTACAGCAAAGCC-3´.  Patients were also genotyped for polymorphisms in 
the C5 exon including the R885H polymorphism associated with poor response to 
eculizumab treatment.(Nishimura, et al., 2014) To amplify this region we used the 
forward primer 5´-GCAGGAGAATTGCTTGAATC-3´ and the reverse primer 5´-
GCACGATTTCAGACTTACAGAA-3´. Automatic sequencing was performed in an ABI 
3730 sequencer using a dye terminator cycle sequencing kit (Applied Biosystems, 
Foster City, CA.). 
 
Flow cytometry 
Erythrocytes from PNH patients were harvested by centrifugation, washed with PBS 
several times until the supernatant remained clear and stored for up to a week in ACD-
A buffer at 4ºC. C3 deposition on erythrocytes and percentage of PNH-E were 
determined simultaneously by 2-color flow cytometry. Briefly, a 0.4% suspension of 
erythrocytes was incubated with a rabbit polyclonal anti human C3 antibody (in house) 
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that recognizes all C3, C3b, iC3b and C3dg at 1μg/mL in PBS for 30 min at room 
temperature (RT). Then we incubated the erythrocytes with an anti-rabbit IgG antibody 
labeled with Alexa 488 (Lifetechnologies) 1μg/mL and with a mouse monoclonal anti-
CD59 labeled with R-Phycoerythrin (Sigma-Aldrich) used in 1:50 dilution for 30min at 
RT to identify PNH-E. FLAER detection of the GPI anchor in granulocytes was 
performed as described previously.(Ahluwalia, et al., 2014) 
 
Free eculizumab levels 
Levels of free eculizumab circulating in the plasma of PNH patients were determined 
by ELISA, essentially as described by Peffault de Latour et al. Wells were coated with 
C5 (10 µl/mL in PBS) overnight at 4oC.  After blocking with Tris-Tween (50mM Tris pH 
7.4, 150mM NaCl, 0.2% Tween 20), containing 1% BSA for 1h at room temperature, 
we added the EDTA-plasma samples diluted 1:8000 in Tris-Tween/1% BSA, and 
incubated them 90min at 37oC. All samples were tested in duplicate. After several 
washes with Tris-Tween/1% BSA, we added a peroxidase-labeled (HRP) goat anti-
human IgG (Dako) antibody and incubated for 1h at RT. For the detection of the 
antibody we used OPD substrate. The reaction was stopped with 10% sulfuric acid. 
Absorbance was measured at 492nm. Sequential dilutions of a known concentration of 
pure eculizumab were used as the calibration curve. 
 
Hemolytic assay CH50 
The CH50 assay was performed using standard procedures. Briefly, sheep 
amboceptor (Siemens) was used to sensitize sheep erythrocytes. Then, 50µl of 
sequential dilutions of the patient serum (from 1/10) in GVB2+ (2.9mM barbital, 1.7mM 
sodium barbital, 144mM NaCl, 0.5mM MgCl2, 0.15mM CaCl2, 0.1% gelatin) were mixed 
with 50µl of sensitized sheep erythrocytes (1 X 109/mL) in GVB2+ and incubated for 
30min at 37oC. Reactions were done in duplicates and with 6 serial dilutions of serum. 
Reactions were stopped by adding 100µl of GVB/10mM EDTA and centrifuged at 
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1800rpm for 5min at 4oC. The supernatants were read at 414nm. Erythrocytes with 
serum in GVB2+/10mM EDTA were used as a blank and erythrocytes with serum and 
water as 100% lysis.  As a calibration curve we used identical dilutions of a normal 
human serum. In these assays, 1/10 dilution of this NHS lyses 100% of sensitized 
sheep erythrocytes.   
 
Dose-response curve to eculizumab 
To determine the minimal concentration of eculizumab necessary to block completely 
the C5 hemolytic activity, we added increasing amounts of eculizumab (from 12.5 to 
200 µg/mL) to the serum of a healthy donor and performed a CH50 assay as described 
previously. These serum samples with eculizumab added were analyzed in parallel to 
detect the free eculizumab levels using the ELISA assay described above. By plotting 
the levels of free eculizumab against CH50 activity values, we established that the 
minimum free eculizumab levels required to completely block C5 activity were 
110±9µg/mL (Figure 3). 
 
Determination of C3 and sC5b-9 plasma levels 
C3 plasma levels were measured by nephelometry as previously described (Siemens 
AG, Germany).  Plasma levels of sC5b-9 were measured by ELISA as follows: 96-well 
plates were coated with a goat anti-mouse IgG2a in PBS at 4ºC overnight. After 
blocking the plates with Tris-Tween/1% BSA for 1h at 37ºC, an appropriate dilution of a 
mouse anti-human TTC antibody (Hycult) was added and the plates incubated for 
another hour at 37ºC. Then, plasma samples diluted 1/10 in Tris-Tween/1% BSA were 
added and incubated for 1h at 37ºC.  sC5b-9 was detected using a mouse anti-human 
C5 monoclonal antibody (IgG1) (in house) for 1h at 37ºC, followed by a peroxidase-
labeled goat anti mouse IgG1 for 30min at 37ºC temperature. For detection we used 
OPD substrate. The reaction was stopped with 10% sulfuric acid. Absorbance was 
measured at 492nm. Sequential dilutions of a human plasma with known 
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concentrations of sC5b-9 were used for the calibration curve. All samples were tested 
in duplicate. 
 
Statistical analysis 
We presented continuous data as mean and standard deviation. When comparing two 
groups, we used the Student’s t-test for normally distributed data. For proportions, we 
used the Pearson chi-square test or the Fisher’s exact test for scarce data. To estimate 
a correlation between percentage of PNH-E and percentage of C3 opsonized 
erythrocytes, correlation pairs were analyzed using Pearson’s correlation test. We 
considered p<0.05 as statistically significant; all statistical tests were two-sided. SPSS 
software, version 21 (SPSS Inc., Chicago, IL, USA) was used for all analyses. 
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RESULTS 
Patient’s response to eculizumab treatment 
Our cohort consists in 12 PNH Spanish patients treated with eculizumab for more 
than 1 year (ranging between 1yr and 8yr; mean 4.3±2.1yr; see Patients, Materials and 
Methods). All patients received 900mg every 14 days, except PNH002, PNH008 and 
PNH018, who received 1200mg every 14 days. Samples from each patient were 
collected during 4 weeks, before and after the eculizumab administration and in the 
intermediate week between two eculizumab cycles. Eculizumab treatment efficiently 
blocked intracellular hemolysis in all patients, which resulted in a significant increase of 
hemoglobin and a dramatic reduction of LDH levels in plasma (Tables 1 and 2). Only 
one of our patients required occasional RBC transfusions during treatment and, 
notably, this was the only patient in our series presenting aplastic anemia (AA-PNH; 
PNH002). All our patients declared a great improvement of their quality of life and none 
failed a single eculizumab administration during the whole length of the treatment. 
Despite this unquestionable success of eculizumab treatment, most of our eculizumab-
treated patients present parameters that suggest persistent low levels hemolysis. Thus, 
83% (10/12) of the PNH patients show elevated reticulocyte counts, 58% (7/12) have 
not completely recovered normal hemoglobin levels, 50% (6/12) have elevated bilirubin 
and 42% (5/12) present slightly elevated LDH levels immediately before eculizumab 
administration (Table 1). These data are consistent with that previously reported by 
Risitano et al.(Risitano, et al., 2009) and Hill et al.(Hill, et al., 2010) in that most 
eculizumab-treated PNH patients present parameters suggesting persistent low-level 
extravascular hemolysis. In our series, however, this residual hemolysis does not 
appear to manifest clinically since our patients, with the exception of the AA-PNH one, 
have not had RBC transfusion requirements. None of our patients carry the 
(Arg885His) C5 polymorphism associated with resistance to eculizumab.(Nishimura, et 
al., 2014) 
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Four PNH patients in our cohort (PNH006, PNH004, PNH018, PNH008) were 
genotyped CR1-H/CR1-L heterozygotes and the remaining eight CR1-H homozygotes. 
Individuals carrying the CR1-H/CR1-H and CR1-H/CR1-L genotypes differ in the 
number of CR1 (CD35) molecules per erythrocyte,(Khera and Das, 2009) which should 
impact on their capacity to control complement alternative pathway activation and C3 
deposition on PNH-E. To offer a figure value to these differences we genotyped three 
large control pedigrees in which we have determined the numbers of CR1 molecules 
per erythrocyte and showed that erythrocytes from CR1-H homozygotes have twice 
and ten times more CR1 (CD35) molecules than erythrocytes from CR1-H/CR1-L and 
CR1-L/CR1-L individuals, respectively (Supplementary Figure 1). Notably, three of the 
CR1-H/CR1-L heterozygote patients in our series were those requiring the highest 
numbers of transfusions/year prior to the eculizumab treatment, two required 
hospitalization due to severe infections and all four CR1-H/CR1-L heterozygote 
patients were included in the group of PNH patients presenting putative extravascular 
hemolysis (Table 1). Moreover, the group of patients carrying the CR1-L allele present, 
after treatment, higher reticulocyte counts (5.1±4% vs 11.1±4%; p=0.04) and plasma 
levels of bilirubin (1.8±1mg/dL vs 4.8±3mg/dL; p=0.03) than the group of CR1-H 
homozygotes.  
 
C3 deposition of PNH erythrocytes 
As indicated, all four CR1-H/CR1-L heterozygote patients in our series were 
included in the group of PNH patients presenting putative extravascular hemolysis 
(Table 1). This is consistent with previous findings showing that extravascular 
hemolysis is a consequence of the uncontrolled C3 activation and progressive C3 
opsonization of the PNH-E that characterizes patients under eculizumab treatment. To 
get further insight into this question, we have studied the PNH-E population and the C3 
fragment deposition in the 12 eculizumab-treated PNH patients in our cohort.  
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The analysis by FLAER of the granulocytes illustrated that in all PNH patients a very 
large percentage of their granulocytes lack the GPI anchor (ranging between 51% and 
99%; mean 82±18%) and therefore are deficient of both, CD55 and CD59 (Table 3). 
There was, however, no correlation between these FLAER data and the percentage of 
CD59 negative erythrocytes (PNH-E) determined by flow cytometry using an anti CD59 
antibody, although individuals carrying the CR1-L allele were those with the highest 
percentage of PNH-E cells (Table 3). Despite the large variability among patients in the 
percentage of PNH-E (ranging between 20% and 94%; mean 65±24%), this 
percentage remained remarkably stable in each individual during the whole period of 
the study (Figure 1a).   
The percentage of cells becoming C3 opsonized in the eculizumab treated patients 
remained also stable overtime and correlated well (r2=0.64; p<0.002) with the 
percentage of PNH-E (Figures 1b and 1c). Seven patients became direct Coombs 
positive (58%) and with one exception they were those presenting more than 25% of 
their PNH-E C3 opsonized (Table 3).  As expected, all four patients carrying the CR1-
H/CR1-L heterozygote genotype were those with the highest % of C3 opsonized PNH-
E and all become direct Coombs-test positive. Crucially, all CR1-H/CR1-L 
heterozygotes presented decreased C3 plasma levels, indicating that continuous 
complement alternative pathway activation in these patients results in massive C3 
consumption (Figure 2a and 2b, Table 3). Consistent with the hypothesis that 
eculizumab-treated PNH patients with highest % of C3 opsonized PNH-E are the likely 
candidates to suffer extravascular hemolysis, reticulocytes counts and bilirubin levels 
were significantly elevated in PNH patients presenting more than 25% of their PNH-E 
C3 opsonized compared with those with C3 opsonized PNH-E under 25% (Figure 2c 
and 2d). 
The observation that CR1-H/CR1-L heterozygote patients develop a partial C3 
deficiency during treatment prompted us to check their medical records for unusual 
frequency or severity of infections. Interestingly, only three patients have had this type 
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of complications during treatment (PNH002, PNH008 and PNH018). PNH002 is the 
AA-PNH patient and have presented with repeated infections likely due to his frequent 
very low counts of neutrophils. PNH008 and PNH018 are patients carrying the CR1-L 
allele, who required hospitalization for 10 and 4 days, respectively, due to severe 
infections of unknown origin (N. meningitides was excluded). Both patients responded 
well to broad-spectrum antibiotics, but required supplemental dosing of eculizumab to 
control hemolysis. Although these data are suggestive that C3 consumption during 
eculizumab treatment in patients carrying the CR1-L allele may render them more 
susceptible to infections, we are aware of the limitations of our small sample and that 
larger series of patients are needed to raise definitive conclusions. 
   
Free eculizumab in plasma of eculizumab-treated PNH patients  
To rule out that the residual low-level hemolysis detected in these patients was 
related to incomplete C5 blockade, we evaluated their free eculizumab in plasma and 
determined their CH50 activity and sC5b-9 levels. Previously, we experimentally 
established that a minimum concentration of 110±9g/mL of free eculizumab in plasma 
is required to confer complete terminal pathway inhibition (Figure 3a). This value is 
significantly higher than the 35g/mL serum concentration of eculizumab that the 
technical note for this drug recommends to assure complete intravascular hemolysis 
blockade. Notably, our value of 110±9g/mL fits well with that recently determined by 
Peffault de Latour et al. to confer complete terminal pathway inhibition.(Peffault de 
Latour, et al., 2015) We measured the circulating free eculizumab levels and the 
activity of the terminal pathway (CH50 and sC5b-9) in all 12 patients in our cohort at 
three time points during two consecutive eculizumab cycles. As expected, levels of free 
eculizumab in all patients increased after eculizumab infusion and decreased 
progressively during the following 14 days (Figure 4). Interestingly, in 2 patients 
(PNH003 and PNH006) levels of free eculizumab fell below the experimentally 
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determined minimum value of 110±9g/mL at the time point previous to the next 
eculizumab administration and in two additional patients (PNH030 and PNH033) the 
free eculizumab levels were close to this value (Figure 3b and Figure 4). CH50 assays 
performed in the 12 PNH patients at all time points were all completely negative and 
patients only occasionally exhibited traces of sC5b-9, indicating that these borderline 
free eculizumab levels do not compromise the complete blockade of C5 activation 
(Figure 4). Consistent with this, no differences were observed between these four 
individuals (free eculizumab levels <150ug/mL) and the rest of the eculizumab-treated 
patients (free eculizumab levels >150ug/mL) for the hemolysis biomarkers assessed in 
these studies (Table 4). Therefore, the evaluation of the free eculizumab levels and 
terminal pathway activity in our cohort demonstrate a complete terminal pathway 
inhibition in all our patients, which indicates that the residual hemolysis detected likely 
involve extravascular mechanisms. 
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DISCUSSION 
Eculizumab treatment efficiently blocked intracellular hemolysis in all our patients, 
which improved significantly their clinical situation.  Notably, only one of our patients 
required occasional RBC transfusions during treatment and likely this was more a 
consequence of the substantial bone marrow failure that presents this patient than a 
suboptimal response to the eculizumab treatment. These data, therefore, deviate from 
earlier reports indicating a heterogeneous response to eculizumab treatment with 25-
35% of the eculizumab-treated patients still requiring RBC transfusions.(Brodsky, et al., 
2008, Luzzatto, et al., 2011, Kelly, et al., 2011) Because these reported suboptimal 
hematological responses were attributed to either extravascular hemolysis or 
incomplete C5 blockade,(Hill, et al., 2010, Risitano, et al., 2009, Peffault de Latour, et 
al., 2015) we assessed hemolysis and complement biomarkers in our PNH patients 
looking for signs of hemolysis. These analyses demonstrated that despite our patients 
have not required RBC transfusions, most of them, in agreement with previous reports, 
present signs of persistent hemolysis (Table 1). Importantly, evaluation of the free 
eculizumab levels and terminal pathway activity data (CH50 and sC5b-9) in all our 
patients demonstrated that this residual hemolysis was not a consequence of 
incomplete blockade of C5 activation. In fact, the patients with signs of on-going 
hemolysis in our cohort characterize by presenting a very high percentage of C3 
opsonized PNH-E, direct Coombs-test positive, high percentage of reticulocytes, 
elevated bilirubin and slightly elevated LDH levels, which fulfills the characteristics 
described earlier by Risitano et al.(Risitano, et al., 2009) and Hill et al.(Hill, et al., 2010) 
for patients undergoing extravascular hemolysis.   
Rondelli et al.(Rondelli, et al., 2014) made the important observation that CR1 
polymorphisms, coding for levels of CR1 (CD35) in erythrocytes, determine the levels 
in which the PNH-E cells are C3 opsonized and that, therefore, influence their 
phagocytosis and extravascular clearance through the reticuloendothelial system in the 
liver and the spleen. Our PNH cohort includes eight CR1-H homozygotes and four 
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CR1-H/CR1-L heterozygotes. We did not found CR1-L homozygotes in this small size 
group. In agreement with previous results,(Roth, et al., 2010, Hill, et al., 2010, Rondelli, 
et al., 2014) all our CR1-H/CR1-L heterozygote patients become direct Coombs-test 
positive after eculizumab treatment due to intense C3 opsonization. We also observed 
a positive correlation between the percentage of PNH-E, reticulocyte counts and levels 
of bilirubin, which is also in agreement with previous reports indicating that carriers of 
the CR1-L allele are particularly predisposed to extravascular hemolysis during 
eculizumab treatment.(Rondelli, et al., 2014) 
Previous studies have reported that the CR1 genotypes did not affect significantly 
their clinical features prior to treatment.(Rondelli, et al., 2014) Interestingly, we noticed 
that CR1-H/CR1-L heterozygote patients, in addition to presenting higher percentages 
of PNH-E in circulation than CR1-H homozygote patients carrying similar sizes of 
granulocyte PNH clones, did receive more transfusions prior to eculizumab treatment. 
We are aware that our numbers are small to raise definitive conclusions. However, 
these data suggest that CR1 (CD35) levels may also be an important disease modifier 
before eculizumab treatment; carriers of CR1-L alleles would require more transfusion 
requirements because they have increased levels of hemolysis.   
Our results also revealed that during eculizumab treatment CR1-H/CR1-L 
heterozygote patients present strong activation of the alternative pathway that results 
in elevated C3 consumption. Unfortunately, we have no data of their plasma C3 levels 
prior to eculizumab treatment to determine whether this is a permanent condition in 
these patients. We have determined C3 levels in all untreated PNH patients in our 
cohort and all presented C3 levels within the normal range (n=16; 128±23mg/dL). This 
group of untreated patients includes 10 patients who are CR1-H/CR1-L heterozygotes. 
However, most of these untreated CR1-H/CR1-L heterozygote patients present PNH 
granulocyte size clones much smaller than those carried by the CR1-H/CR1-L 
heterozygote PNH treated patients (1% to 61%; 19±24% vs 62% to 99%; 88±17%). 
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The observation that CR1-H/CR1-L heterozygote patients develop a partial plasma 
C3 deficiency as a consequence of the strong alternative pathway activation that take 
place on the surface of their PNH-E raises the possibility that these patients may have 
an increased susceptibility to infections than those who are CR1-H homozygotes. 
Three mechanisms are crucial in the complement-mediated host defense against 
bacterial infections: 1) direct killing by the terminal pathway; 2) recruitment of 
phagocytic cells at the site of infection by the C5a anaphylotoxin; and 3) C3 
opsonization for immune-recognition. In eculizumab-treated patients with complete 
blockade of the terminal pathway, an intact opsonization mechanism is essential for 
efficient phagocytosis and intracellular killing of bacteria. This mechanism depends on 
C3 levels. Not surprisingly, similarly to individuals with primary deficiency of C3, it has 
been reported that patients with acquired C3 deficiencies have increased 
predisposition to infectious disease.(Ram, et al., 2010, Homann, et al., 1997)As 
indicated before, we are aware that further studies with larger cohort are needed to 
raise definitive conclusions. However, our observation that the only patients in our 
cohort requiring hospitalization due to infections were two CR1-H/CR1-L heterozygote 
carriers may be a sign that special attention should be given to PNH patients carrying 
the CR1-L allele when they are treated with eculizumab. 
In conclusion, our study confirms that despite complete C5 blockade, most 
eculizumab-treated patients show persistent signs of low-level hemolysis, which likely 
corresponds to the extracellular removal of the heavily C3 opsonized PNH-E that 
generate during the eculizumab treatment. The clinical relevance of this residual 
hemolysis is however contentious; in our patients, this residual hemolysis has no 
clinical manifestations as illustrated by the fact that the only patient requiring additional 
RBC transfusions presents aplastic anemia. Notably, we also show that on-going 
alternative pathway activation in eculizumab-treated PNH patients carrying the CR1-L 
allele results in an acquired partial C3 deficiency that could, potentially, increase their 
susceptibility to infections. Finally, we provide further evidence that the evaluation of 
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the free eculizumab levels and terminal pathway activity data offers useful information 
to personalize eculizumab administration. 
 20 
ACKNOWLEDGEMENTS 
We are in debt to all patients and relatives participating in this study. S.RdeC is 
supported by the Spanish “Ministerio de Economía y Competitividad” (SAF2011-
26583) and the Autonomous Region of Madrid (S2010/BMD-2316). 
DISCLOUSURE OF CONFLICTS OF INTEREST: 
SRdeC, AV and EO have received honoraria from Alexion Pharmaceuticals for 
giving lectures and participating in advisory boards. None of these activities has had 
any influence on the results or interpretation in this article. Other authors declare no 
conflicts of interest. 
 21 
REFERENCES 
 Wilcox, L.A., Ezzell, J.L., Bernshaw, N.J., Parker, C.J. 1991. Molecular basis of the 
enhanced susceptibility of the erythrocytes of paroxysmal nocturnal 
hemoglobinuria to hemolysis in acidified serum. Blood 78, 820. 
Takeda, J., Miyata, T., Kawagoe, K., Iida, Y., Endo, Y., Fujita, T., Takahashi, M., Kitani, 
T., Kinoshita, T. 1993. Deficiency of the GPI anchor caused by a somatic 
mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 73, 
703. 
Miyata, T., Takeda, J., Iida, Y., Yamada, N., Inoue, N., Takahashi, M., Maeda, K., 
Kitani, T., Kinoshita, T. 1993. The cloning of PIG-A, a component in the early 
step of GPI-anchor biosynthesis. Science 259, 1318. 
Thomas, T.C., Rollins, S.A., Rother, R.P., Giannoni, M.A., Hartman, S.L., Elliott, E.A., 
Nye, S.H., Matis, L.A., Squinto, S.P., Evans, M.J. 1996. Inhibition of 
complement activity by humanized anti-C5 antibody and single-chain Fv. Mol 
Immunol 33, 1389. 
Rother, R.P., Rollins, S.A., Mojcik, C.F., Brodsky, R.A., Bell, L. 2007. Discovery and 
development of the complement inhibitor eculizumab for the treatment of 
paroxysmal nocturnal hemoglobinuria. Nat Biotechnol 25, 1256. 
Hillmen, P., Hall, C., Marsh, J.C., Elebute, M., Bombara, M.P., Petro, B.E., Cullen, 
M.J., Richards, S.J., Rollins, S.A., Mojcik, C.F., Rother, R.P. 2004. Effect of 
eculizumab on hemolysis and transfusion requirements in patients with 
paroxysmal nocturnal hemoglobinuria. N Engl J Med 350, 552. 
Hillmen, P., Young, N.S., Schubert, J., Brodsky, R.A., Socie, G., Muus, P., Roth, A., 
Szer, J., Elebute, M.O., Nakamura, R., Browne, P., Risitano, A.M., Hill, A., 
Schrezenmeier, H., Fu, C.L., Maciejewski, J., Rollins, S.A., Mojcik, C.F., Rother, 
R.P., Luzzatto, L. 2006. The complement inhibitor eculizumab in paroxysmal 
nocturnal hemoglobinuria. N Engl J Med 355, 1233. 
 22 
Brodsky, R.A., Young, N.S., Antonioli, E., Risitano, A.M., Schrezenmeier, H., Schubert, 
J., Gaya, A., Coyle, L., de Castro, C., Fu, C.L., Maciejewski, J.P., Bessler, M., 
Kroon, H.A., Rother, R.P., Hillmen, P. 2008. Multicenter phase 3 study of the 
complement inhibitor eculizumab for the treatment of patients with paroxysmal 
nocturnal hemoglobinuria. Blood 111, 1840. 
Luzzatto, L., Gianfaldoni, G., Notaro, R. 2011. Management of paroxysmal nocturnal 
haemoglobinuria: a personal view. Br J Haematol 153, 709. 
Kelly, R.J., Hill, A., Arnold, L.M., Brooksbank, G.L., Richards, S.J., Cullen, M., Mitchell, 
L.D., Cohen, D.R., Gregory, W.M., Hillmen, P. 2011. Long-term treatment with 
eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and 
improved survival. Blood 117, 6786. 
Logue, G.L., Rosse, W.F., Adams, J.P. 1973. Mechanisms of immune lysis of red 
blood cells in vitro. I. Paroxysmal nocturnal hemoglobinuria cells. J Clin Invest 
52, 1129. 
Roth, A., Peine, S., Duhrsen, U. 2010. Paroxysmal nocturnal hemoglobinuria turning 
Coombs-positive. Int J Hematol 91, 159. 
Hill, A., Rother, R.P., Arnold, L., Kelly, R., Cullen, M.J., Richards, S.J., Hillmen, P. 
2010. Eculizumab prevents intravascular hemolysis in patients with paroxysmal 
nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis 
occurring through C3 opsonization. Haematologica 95, 567. 
Jaffe, C.J., Atkinson, J.P., Frank, M.M. 1976. The role of complement in the clearance 
of cold agglutinin-sensitized erythrocytes in man. J Clin Invest 58, 942. 
Ross, G.D., Lambris, J.D. 1982. Identification of a C3bi-specific membrane 
complement receptor that is expressed on lymphocytes, monocytes, 
neutrophils, and erythrocytes. J Exp Med 155, 96. 
 
 23 
Lin, Z., Schmidt, C.Q., Koutsogiannaki, S., Ricci, P., Ricklin, D., Risitano, A.M., 
Lambris, J.D. 2015. Complement C3dg-mediated erythrophagocytosis: 
implications for paroxysmal nocturnal hemoglobinuria.  126, 891. 
Risitano, A.M., Notaro, R., Marando, L., Serio, B., Ranaldi, D., Seneca, E., Ricci, P., 
Alfinito, F., Camera, A., Gianfaldoni, G., Amendola, A., Boschetti, C., Di Bona, 
E., Fratellanza, G., Barbano, F., Rodeghiero, F., Zanella, A., Iori, A.P., Selleri, 
C., Luzzatto, L., Rotoli, B. 2009. Complement fraction 3 binding on erythrocytes 
as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria 
patients treated by eculizumab. Blood 113, 4094. 
Rodriguez de Cordoba, S., Rubinstein, P. 1986. Quantitative variations of the C3b/C4b 
receptor (CR1) in human erythrocytes are controlled by genes within the 
regulator of complement activation (RCA) gene cluster. J Exp Med 164, 1274. 
Wilson, J.G., Murphy, E.E., Wong, W.W., Klickstein, L.B., Weis, J.H., Fearon, D.T. 
1986. Identification of a restriction fragment length polymorphism by a CR1 
cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med 164, 
50. 
Rondelli, T., Risitano, A.M., Peffault de Latour, R., Sica, M., Peruzzi, B., Ricci, P., 
Barcellini, W., Iori, A.P., Boschetti, C., Valle, V., Fremeaux-Bacchi, V., De 
Angioletti, M., Socie, G., Luzzatto, L., Notaro, R. 2014. Polymorphism of the 
complement receptor 1 gene correlates with the hematologic response to 
eculizumab in patients with paroxysmal nocturnal hemoglobinuria. 
Haematologica 99, 262. 
Peffault de Latour, R., Fremeaux-Bacchi, V., Porcher, R., Xhaard, A., Rosain, J., 
Castaneda, D.C., Vieira-Martins, P., Roncelin, S., Rodriguez-Otero, P., 
Plessier, A., Sicre de Fontbrune, F., Abbes, S., Robin, M., Socie, G. 2015. 
Assessing complement blockade in patients with paroxysmal nocturnal 
hemoglobinuria receiving eculizumab. Blood 125, 775. 
 24 
Munoz-Linares, C., Ojeda, E., Fores, R., Pastrana, M., Cabero, M., Morillo, D., 
Bautista, G., Banos, I., Monteserin, C., Bravo, P., Jaro, E., Cedena, T., 
Steegmann, J.L., Villegas, A., Cabrera, J.R. 2014. Paroxysmal nocturnal 
hemoglobinuria: a single Spanish center's experience over the last 40 yr. Eur J 
Haematol 93, 309. 
Nakakuma, H., Kawaguchi, T., Horikawa, K., Hidaka, M., Nagakura, S., Iwamoto, N., 
Kagimoto, T., Takatsuki, K. 1995. Proposal for a classification of the clinical 
stages of paroxysmal nocturnal hemoglobinuria. Blood 86, 2051. 
Parker, C., Omine, M., Richards, S., Nishimura, J., Bessler, M., Ware, R., Hillmen, P., 
Luzzatto, L., Young, N., Kinoshita, T., Rosse, W., Socie, G. 2005. Diagnosis 
and management of paroxysmal nocturnal hemoglobinuria. Blood 106, 3699. 
Miller, S.A., Dykes, D.D., Polesky, H.F. 1988. A simple salting out procedure for 
extracting DNA from human nucleated cells. Nucleic Acids Res 16, 1215. 
Nishimura, J., Yamamoto, M., Hayashi, S., Ohyashiki, K., Ando, K., Brodsky, A.L., Noji, 
H., Kitamura, K., Eto, T., Takahashi, T., Masuko, M., Matsumoto, T., Wano, Y., 
Shichishima, T., Shibayama, H., Hase, M., Li, L., Johnson, K., Lazarowski, A., 
Tamburini, P., Inazawa, J., Kinoshita, T., Kanakura, Y. 2014. Genetic variants 
in C5 and poor response to eculizumab. N Engl J Med 370, 632. 
Ahluwalia, J., Naseem, S., Sachdeva, M.U., Bose, P., Bose, S.K., Kumar, N., Thapa, 
B.R., Varma, N., Chawla, Y.K. 2014. Paroxysmal Nocturnal Hemoglobinuria is 
rare cause for thrombosis of the intra-abdominal veins in the ethnic Indian 
population - results from FLAER-based flowcytometry screening. Eur J 
Haematol 92, 435. 
Khera, R., Das, N. 2009. Complement Receptor 1: disease associations and 
therapeutic implications. Mol Immunol 46, 761. 
Ram, S., Lewis, L.A., Rice, P.A. 2010. Infections of people with complement 
deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev 
23, 740. 
 25 
Homann, C., Varming, K., Hogasen, K., Mollnes, T.E., Graudal, N., Thomsen, A.C., 
Garred, P. 1997. Acquired C3 deficiency in patients with alcoholic cirrhosis 
predisposes to infection and increased mortality. Gut 40, 544. 
Geffre, A., Concordet, D., Braun, J.P., Trumel, C. 2011. Reference Value Advisor: a 
 new freeware set of macroinstructions to calculate reference intervals with 
 Microsoft Excel. Vet Clin Pathol 40, 107. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 26 
Table 1. Hematological and genetic markers in eculizumab-treated PNH patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Values are mean ± standard deviation of determinations at all time points.  
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Table 2. Changes in hemolysis parameters in PNH patients after eculizumab treatment 
 
 
 
 
 
 
 
 
 
   *Values are mean ± standard deviation of all individuals included in each category. Statistical analysis was   
   performed using Student´s t test.
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     Table 3. C3 levels in plasma and in erythrocytes of eculizumab treated PNH patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  *Values are mean ± standard deviation of determinations at all time points. 
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Table 4. Hemolysis and complement parameters in PNH patients according to free eculizumab in plasma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  * Values are mean ± standard deviation or proportions of all individuals included in each category. For the statistical   
  analysis we used Student´s t-test to compare continuous variables or Fisher´s exact test for the comparison of proportions.
 
 
LEGENDS FOR FIGURES 
 
Figure 1. PNH-E cells and C3 opsonized erythrocytes in eculizumab-treated patients 
a) Percentage of PNH-E cells determined by flow cytometry as CD59 negative 
erythrocytes at different time points during two consecutive eculizumab cycles. b) 
Percentage of C3 opsonized erythrocytes determined by flow cytometry using a goat 
polyclonal anti human C3 at different time points during two consecutive eculizumab 
cycles. Samples at day 0 and 14 correspond to those obtained prior and after the 
eculizumab administration. Each point corresponds to the mean value ± standard 
deviation of three independent measurements. The correspondence of the symbols 
with the individual patients is depicted at the bottom of the figure. c) Correlation 
between percentage of PNH-E cells and percentage of C3 opsonized erythrocytes for 
the mean of values obtained at all time points. Pearson correlation analysis shows a 
significant positive correlation (r2 = 0.64; p<0.002). 
 
Figure 2. CR1-L associates with high % of PNH-E, high % of C3 opsonized cells, 
decreased C3 plasma levels and elevated hemolysis parameters. 
Figures depict the comparison of the mean value ± standard deviation of the individual 
values (mean of determinations at all time points) obtained for CR1-H homozygote 
(n=8) and CR1-H/CR1-L heterozygote (n=4) patients.  
 
Figure 3. Determination of free-eculizumab levels in the plasma of treated PNH 
patients 
a) Determination of the minimal circulating level of free eculizumab required for 
blocking completely the activity of the lytic pathway, measured as % of lysis in a CH50 
assay (see Materials and Methods). 
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b) Mean value ± standard deviation of circulating free eculizumab in the plasma of 
patients prior to the next administration of eculizumab. Data from time points 0 and 14 
days are included. 
 
Figure 4. Individual variations in free eculizumab levels, sC5b-9 and CH50 during 
treatment with eculizumab 
Individual representations of the free eculizumab levels (g/mL; empty circles) and 
sC5b-9 levels (ng/mL; solid squares) at all time points during two consecutive cycles of 
eculizumab treatment. The horizontal line represents the minimal concentration 
(110g/mL) of free eculizumab required for blocking completely the lytic pathway. The 
same line also corresponds to the upper limit of the normal levels of plasma sC5b-9 in 
this assay, calculated using reference value advisor v2.1 as described by Geffre et al 
(Geffre, et al., 2011). 
 
 
 
 
 
 
 
 
 




